Influenza virus resistance to antiviral agents: A plea for rational use

Gregory A. Poland, Robert M. Jacobson, Inna G. Ovsyannikova

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents. At the current time, nearly all influenza A/H3N2 viruses and a percentage of influenza A/H1N1 viruses are adamantane resistant, which leaves only neuraminidase inhibitors available for treatment of infection with these viruses. In December 2008, the Centers for Disease Control and Prevention released new data demonstrating that a high percentage of circulating influenza A/H1N1 viruses are now resistant to oseltamivir. In addition, oseltamivir-resistant influenza B and A/H5N1 viruses have been identified. Thus, use of monotherapy for influenza virus infection is irrational and may contribute to mutational pressure for further selection of antiviral-resistant strains. History has demonstrated that monotherapy for influenza virus infection leads to resistance, resulting in the use of a new monotherapy agent followed by resistance to that new agent and thus resulting in a background of viruses resistant to both drugs. We argue that combination antiviral therapy, new guidelines for indications for treatment, point-of-care diagnostic testing, and a universal influenza vaccination recommendation are critical to protecting the population against influenza virus and to preserving the benefits of antiviral agents.

Original languageEnglish (US)
Pages (from-to)1254-1256
Number of pages3
JournalClinical Infectious Diseases
Volume48
Issue number9
DOIs
StatePublished - May 1 2009

Fingerprint

Virus Diseases
Orthomyxoviridae
Antiviral Agents
Influenza A virus
Oseltamivir
H1N1 Subtype Influenza A Virus
Human Influenza
Adamantane
H3N2 Subtype Influenza A Virus
H5N1 Subtype Influenza A Virus
Influenza Vaccines
Neuraminidase
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Vaccination
History
Guidelines
Viruses
Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Cite this

Influenza virus resistance to antiviral agents : A plea for rational use. / Poland, Gregory A.; Jacobson, Robert M.; Ovsyannikova, Inna G.

In: Clinical Infectious Diseases, Vol. 48, No. 9, 01.05.2009, p. 1254-1256.

Research output: Contribution to journalArticle

Poland, GA, Jacobson, RM & Ovsyannikova, IG 2009, 'Influenza virus resistance to antiviral agents: A plea for rational use', Clinical Infectious Diseases, vol. 48, no. 9, pp. 1254-1256. https://doi.org/10.1086/598989
Poland, Gregory A. ; Jacobson, Robert M. ; Ovsyannikova, Inna G. / Influenza virus resistance to antiviral agents : A plea for rational use. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 9. pp. 1254-1256.
@article{b24b168d2d1b4ce48659bb334f206de4,
title = "Influenza virus resistance to antiviral agents: A plea for rational use",
abstract = "Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents. At the current time, nearly all influenza A/H3N2 viruses and a percentage of influenza A/H1N1 viruses are adamantane resistant, which leaves only neuraminidase inhibitors available for treatment of infection with these viruses. In December 2008, the Centers for Disease Control and Prevention released new data demonstrating that a high percentage of circulating influenza A/H1N1 viruses are now resistant to oseltamivir. In addition, oseltamivir-resistant influenza B and A/H5N1 viruses have been identified. Thus, use of monotherapy for influenza virus infection is irrational and may contribute to mutational pressure for further selection of antiviral-resistant strains. History has demonstrated that monotherapy for influenza virus infection leads to resistance, resulting in the use of a new monotherapy agent followed by resistance to that new agent and thus resulting in a background of viruses resistant to both drugs. We argue that combination antiviral therapy, new guidelines for indications for treatment, point-of-care diagnostic testing, and a universal influenza vaccination recommendation are critical to protecting the population against influenza virus and to preserving the benefits of antiviral agents.",
author = "Poland, {Gregory A.} and Jacobson, {Robert M.} and Ovsyannikova, {Inna G.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1086/598989",
language = "English (US)",
volume = "48",
pages = "1254--1256",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Influenza virus resistance to antiviral agents

T2 - A plea for rational use

AU - Poland, Gregory A.

AU - Jacobson, Robert M.

AU - Ovsyannikova, Inna G.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents. At the current time, nearly all influenza A/H3N2 viruses and a percentage of influenza A/H1N1 viruses are adamantane resistant, which leaves only neuraminidase inhibitors available for treatment of infection with these viruses. In December 2008, the Centers for Disease Control and Prevention released new data demonstrating that a high percentage of circulating influenza A/H1N1 viruses are now resistant to oseltamivir. In addition, oseltamivir-resistant influenza B and A/H5N1 viruses have been identified. Thus, use of monotherapy for influenza virus infection is irrational and may contribute to mutational pressure for further selection of antiviral-resistant strains. History has demonstrated that monotherapy for influenza virus infection leads to resistance, resulting in the use of a new monotherapy agent followed by resistance to that new agent and thus resulting in a background of viruses resistant to both drugs. We argue that combination antiviral therapy, new guidelines for indications for treatment, point-of-care diagnostic testing, and a universal influenza vaccination recommendation are critical to protecting the population against influenza virus and to preserving the benefits of antiviral agents.

AB - Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents. At the current time, nearly all influenza A/H3N2 viruses and a percentage of influenza A/H1N1 viruses are adamantane resistant, which leaves only neuraminidase inhibitors available for treatment of infection with these viruses. In December 2008, the Centers for Disease Control and Prevention released new data demonstrating that a high percentage of circulating influenza A/H1N1 viruses are now resistant to oseltamivir. In addition, oseltamivir-resistant influenza B and A/H5N1 viruses have been identified. Thus, use of monotherapy for influenza virus infection is irrational and may contribute to mutational pressure for further selection of antiviral-resistant strains. History has demonstrated that monotherapy for influenza virus infection leads to resistance, resulting in the use of a new monotherapy agent followed by resistance to that new agent and thus resulting in a background of viruses resistant to both drugs. We argue that combination antiviral therapy, new guidelines for indications for treatment, point-of-care diagnostic testing, and a universal influenza vaccination recommendation are critical to protecting the population against influenza virus and to preserving the benefits of antiviral agents.

UR - http://www.scopus.com/inward/record.url?scp=65549113423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549113423&partnerID=8YFLogxK

U2 - 10.1086/598989

DO - 10.1086/598989

M3 - Article

C2 - 19323631

AN - SCOPUS:65549113423

VL - 48

SP - 1254

EP - 1256

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -